Apaf-1 inhibitors protect from unwanted cell death in In vivo models of kidney ischemia and chemotherapy induced ototoxicity

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Orzáez, Mar ^a   Sancho, Monica ^a   Marchán, Sandra ^b   Mondragón, Laura ^a   Montava, Rebeca ^a   Valero, Juan García ^c   Landeta, Olatz ^c   Basañez, Gorka ^c   Carbajo, Rodrigo J ^a   Pineda Lucena, Antonio ^a   Bujons, Jordi ^d   Moure, Alejandra ^d   Messeguer, Angel ^d   Lagunas, Carmen ^b   Herrero, Carmen ^b   Pérez Payá, Enrique ^a,e  

^a CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^b Laboratoris SALVAT SA   (Spain)

^c CSIC UPV Unidad de Biofisica UBF   (Spain)

^d INSTITUTE OF ADVANCED CHEMISTRY OF CATALONIA IQAC CSIC   (Spain)

^e INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSOME; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CISPLATIN; CYTOCHROME C; CYTOPROTECTIVE AGENT; EBSELEN; EMRICASAN; PROCASPASE 9; SVT 016426; SVT 016448; SVT 017686; SVT 017923; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APAF1 PROTEIN, HUMAN; APAF1 PROTEIN, MOUSE; APAF1 PROTEIN, RAT; FUSED HETEROCYCLIC RINGS; ZEBRAFISH PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROTECTION; CLONOGENESIS; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; EMBRYO; ENZYME ACTIVATION; ENZYME RELEASE; EX VIVO STUDY; FIBROBLAST; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; KIDNEY ISCHEMIA; MALE; MOUSE; NONHUMAN; OTOTOXICITY; RAT; ZEBRA FISH; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; HEARING IMPAIRMENT; HELA CELL LINE; KIDNEY; KIDNEY DISEASE; METABOLISM; PATHOLOGY; REPERFUSION INJURY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CELL DEATH; CISPLATIN; DISEASE MODELS, ANIMAL; HEARING LOSS; HELA CELLS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MICE; RATS; REPERFUSION INJURY; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84908191401     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110979     Document Type: Article

References (54)

1. Wang C, Youle RJ (2009) The role of mitochondria in apoptosis. Annu Rev Genet 43: 95-118.
2. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X (1997) Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90: 405-413.
3. Green DR, Kroemer G (2005) Pharmacological manipulation of cell death: clinical applications in sight? J Clin Invest 115: 2610-2617.
4. Linton SD (2005) Caspase inhibitors: a pharmaceutical industry perspective. Curr Top Med Chem 5: 1697-1717.
5. Yaoita H, Ogawa K, Maehara K, Maruyama Y (2000) Apoptosis in relevant clinical situations: contribution of apoptosis in myocardial infarction. Cardiovasc Res 45: 630-641.
6. Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150.
7. Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, et al. (2004) Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a livertargeted caspase inhibitor. J Pharmacol Exp Ther 309: 634-640.
8. McCall M, Toso C, Emamaullee J, Pawlick R, Edgar R, et al. (2011) The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islet transplantation in mice. Surgery 150: 48-55.
9. Burgess G, Ayoub A, Leblanc B, Gropp K, Kawabata T, et al. (2008) Treatment with the pancaspase inhibitor PF-03491390, resulted in atypical cellular infiltrates in mouse and rat liver. Cell: iiA-ivA, 1A-1241A.
10. Mochizuki H, Hayakawa H, Migita M, Shibata M, Tanaka R, et al. (2001) An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 98: 10918-10923. Epub 12001 Sep 10914.
11. Gao Y, Liang W, Hu X, Zhang W, Stetler RA, et al. (2009) Neuroprotection against hypoxic-ischemic brain injury by inhibiting the apoptotic protease activating factor-1 pathway. Stroke 41: 166-172.
12. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES (1998) Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1: 949-957.
13. Malet G, Martin AG, Orzaez M, Vicent MJ, Masip I, et al. (2006) Small molecule inhibitors of Apaf-1-related caspase- 3/-9 activation that control mitochondrial-dependent apoptosis. Cell Death Differ 13: 1523-1532.
14. Mondragon L, Galluzzi L, Mouhamad S, Orzaez M, Vicencio JM, et al. (2009) A chemical inhibitor of Apaf-1 exerts mitochondrioprotective functions and interferes with the intra-S-phase DNA damage checkpoint. Apoptosis 14: 182-190.
15. Riedl SJ, Li W, Chao Y, Schwarzenbacher R, Shi Y (2005) Structure of the apoptotic protease-activating factor 1 bound to ADP. Nature 434: 926-933.
16. Dalvit C, Pevarello P, Tato M, Veronesi M, Vulpetti A, et al. (2000) Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J Biomol NMR 18: 65-68.
17. Meyer B, Peters T (2003) NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew Chem Int Ed Engl 42: 864-890.
18. Zou H, Li Y, Liu X, Wang X (1999) An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274: 11549-11556.
19. Feng BY, Simeonov A, Jadhav A, Babaoglu K, Inglese J, et al. (2007) A high-throughput screen for aggregation-based inhibition in a large compound library. J Med Chem 50: 2385-2390.
20. Linton SD, Aja T, Armstrong RA, Bai X, Chen LS, et al. (2005) First-in-class pan caspase inhibitor developed for the treatment of liver disease. J Med Chem 48: 6779-6782.
21. Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B (2000) Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 275: 33585-33592.
22. Slattery EL, Warchol ME (2010) Cisplatin ototoxicity blocks sensory regeneration in the avian inner ear. J Neurosci 30: 3473-3481.
23. Ton C, Parng C (2005) The use of zebrafish for assessing ototoxic and otoprotective agents. Hear Res 208: 79-88.
24. Sadis C, Teske G, Stokman G, Kubjak C, Claessen N, et al. (2007) Nicotine protects kidney from renal ischemia/reperfusion injury through the cholinergic anti-inflammatory pathway. PLoS ONE 2: e469.
25. Eltzschig HK, Eckle T (2011) Ischemia and reperfusion-from mechanism to translation. Nat Med 17: 1391-1401.
26. Bruick RK (2000) Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci U S A 97: 9082-9087.
27. Laskowski IA, Hancock WW, Pratchke J, Wilhelm MJ, Tilney NL (2001) Accelerated graft dysfunction in renal isografts from non-heart-beating donors. Transplant Proc 33: 909-910.
28. Reubold TF, Wohlgemuth S, Eschenburg S (2011) Crystal structure of full-length Apaf-1: how the death signal is relayed in the mitochondrial pathway of apoptosis. Structure 19: 1074-1083.
29. Sarker KP, Biswas KK, Rosales JL, Yamaji K, Hashiguchi T, et al. (2003) Ebselen inhibits NO-induced apoptosis of differentiated PC12 cells via inhibition of ASK1-p38 MAPK-p53 and JNK signaling and activation of p44/42 MAPK and Bcl-2. J Neurochem 87: 1345-1353.
30. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, et al. (2010) Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol 55: 2201-2209.
31. Kroemer G, Martin SJ (2005) Caspase-independent cell death. Nat Med 11: 725-730.
32. Franklin EE, Robertson JD (2007) Requirement of Apaf-1 for mitochondrial events and the cleavage or activation of all procaspases during genotoxic stress-induced apoptosis. Biochem J 405: 115-122.
33. Ferraro E, Pesaresi MG, De Zio D, Cencioni MT, Gortat A, et al. (2011) Apaf1 plays a pro-survival role by regulating centrosome morphology and function. J Cell Sci 124: 3450-3463.
34. Potokar M, Kreft M, Chowdhury HH, Vardjan N, Zorec R (2006) Subcellular localization of Apaf-1 in apoptotic rat pituitary cells. Am J Physiol Cell Physiol 290: C672-677.
35. Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, et al. (2008) Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135: 1074-1084.
36. Rybak LP, Mukherjea D, Jajoo S, Ramkumar V (2009) Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 219: 177-186.
37. Yoo J, Hamilton SJ, Angel D, Fung K, Franklin J, et al. (2014) Cisplatin otoprotection using transtympanic L-N-acetylcysteine: A pilot randomized study in head and neck cancer patients. Laryngoscope.
38. Ardura JA, Sanz AB, Ortiz A, Esbrit P (2013) Parathyroid hormone-related protein protects renal tubuloepithelial cells from apoptosis by activating transcription factor Runx2. Kidney Int 83: 825-834.
39. Moure A, Sanclimens G, Bujons J, Masip I, Alvarez-Larena A, et al. (2011) Chemical modulation of peptoids: synthesis and conformational studies on partially constrained derivatives. Chemistry 17: 7927-7939.
40. Fearnhead HO (2001) Cell-free systems to study apoptosis. Methods Cell Biol 66: 167-185.
41. (2011) Schrödinger Suite 2011. New York, NY: Schrödinger, LLC.
42. (2011) Maestro, version 9.2. New York, NY: Schrödinger, LLC.
43. (2011) MacroModel, version 9.9. New York, NY: Schrödinger, LLC.
44. Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. J Am Chem Soc 118: 11225-11236.
45. Still WC, Tempczyk A, Hawley RC, Hendrickson T (1990) Semianalytical treatment of solvation for molecular mechanics and dynamics. Journal of the American Chemical Society 112: 6127-6129.
46. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. NucleicAcidsRes 28: 235-242.
47. (2011) SiteMap, version 2.5. New York, NY: Schrödinger, LLC.
48. Halgren T (2007) New method for fast and accurate binding-site identification and analysis. Chem Biol Drug Des 69: 146-148.
49. Halgren TA (2009) Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 49: 377-389.
50. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47: 1739-1749.
51. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, et al. (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49: 6177-6196.
52. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, et al. (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47: 1750-1759.
53. (2011) LigPrep, version 2.5. New York, NY: Schrödinger, LLC.
54. Cecconi F, Alvarez-Bolado G, Meyer BI, Roth KA, Gruss P (1998) Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell 94: 727-737.